Research into Dravet syndrome spans multiple therapeutic approaches and trial phases.

16 total trials for this combination

Showing top 10 of 16 trials

Trials

NCT ID	Title	Status	Phase
NCT03650452	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies	COMPLETED	PHASE2
NCT03936777	A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome	COMPLETED	PHASE3
NCT05364021	Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	COMPLETED	PHASE1/PHASE2
NCT02091206	A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)	COMPLETED	PHASE2
NCT02224703	GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	COMPLETED	PHASE3
NCT02823145	An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome	COMPLETED	PHASE3
NCT06872125	A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome	RECRUITING	PHASE3
NCT06660394	A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)	RECRUITING	—
NCT02682927	A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome	COMPLETED	PHASE3
NCT02091375	Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)	COMPLETED	PHASE3

Related Pages

All Dravet syndrome trials All trials in Miami, United States